0
0

Cart (0)

Home > SIL NDSRI's > Nebivolol

Nebivolol -SIL NDSRI's
Wishlist
Select options

Nitroso Nebivolol D4

  • CAT NUMBER DCTI-A-301
  • CAS NUMBER NA
  • MOLECULAR FORMULA C22H20D4F2N2O5
  • MOLECULAR WEIGHT 438.46
Select options
Wishlist
References
FAQ's

References

  1. Trinka, Peter; Reiter, Jozsef; Berecz, Gabor; Simig, Gyula, New Process For The Preparation Of Racemic ([2S[2R*[R[R*]]]] And ([2R[2S*[S[S*]]]]-(±)- Α,Α' -[Imino-Bis(Methylene)]Bis[6-Fluorochroman-2-Methanol] AND ITS PURE [2S[2R*[R[R*]&, Egis Gyogyszergyar Rt., Hungary, WO2004041805A1, May 21, 2004
  2. Ramakrishna, N. V. S.; Vishwottam, K. N.; Koteshwara, M.; Manoj, S.; Santosh, M.; Varma, D. P., Rapid quantification of Nebivolol in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry, Journal of Pharmaceutical and Biomedical Analysis, Volume: 39, Issue: 5, Pages: 1006-1013, 2005

Frequently Asked Questions

Analytical Methods like reverse-phase ultra-performance liquid chromatographic method help estimate Nebivolol impurities quantitatively.

Yes, impurities in Nebivolol can impact patient safety. Depending on their nature and concentration, contaminants can cause adverse effects or reduce the efficacy of the medication.

Methanol is employed to attain the ideal solubility and differentiation of impurities in Nebivolol.

Nebivolol impurities should generally be stored at a controlled room temperature between 2-8 ⁰C or as indicated on the Certificate of Analysis (CoA).

Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.

Back to Top
Product has been added to your cart
jQuery(window).on('load', function() { $('input[name="productname"]').val($('.product_title').html()); });